Zhu Baomin, Yu Lianling, Yue QingCai
Department of Blood Transfusion, Linyi People's Hospital, Linyi, Shandong, PR China.
Department of Endocrinology, Linyi People's Hospital, Linyi, Shandong, PR China.
Biomed Pharmacother. 2017 Jul;91:287-294. doi: 10.1016/j.biopha.2017.02.112. Epub 2017 May 2.
Chemotherapy is the current standard treatment for Non-Hodgkin's lymphoma (NHL). Combination therapy is emerging as an important strategy for a better long-term prognosis with decreased side effects, maximized therapeutic effect. The aim of this study is to deliver vincristine (VCR) and quercetin (QU) with synergistic drug ratios through lipid-polymeric nanocarriers (LPNs) for the lymphoma combination chemotherapy METHODS: In this present study, we constructed VCR and QU dual-loaded LPNs (VCR/QU LPNs) and investigated their antitumor efficacy in vitro cell culture models and a tumor xenograft mouse model.
The formulated VCR/QU LPNs exhibited nano-size, negative zeta potential with sustained release profile in vitro. The dual drug loaded LPNs exhibited the best antitumor efficacy in vitro and in vivo.
It could be concluded that VCR/QU LPNs can combine the efficiency of these two drugs, bring about synergistic effect. Co-encapsulation of VCR and QN in the same LPNs has potential as a novel therapeutic approach to overcome chemo-resistant lymphoma.
化疗是目前非霍奇金淋巴瘤（NHL）的标准治疗方法。联合治疗正成为一种重要策略，以实现更好的长期预后，同时减少副作用并最大化治疗效果。本研究的目的是通过脂质-聚合物纳米载体（LPNs）以协同药物比例递送长春新碱（VCR）和槲皮素（QU）用于淋巴瘤联合化疗。方法：在本研究中，我们构建了VCR和QU双载LPNs（VCR/QU LPNs），并在体外细胞培养模型和肿瘤异种移植小鼠模型中研究了它们的抗肿瘤功效。结果：所制备的VCR/QU LPNs呈现纳米尺寸、负zeta电位，且在体外具有缓释特性。双药负载的LPNs在体外和体内均表现出最佳的抗肿瘤功效。结论：可以得出结论，VCR/QU LPNs能够结合这两种药物的效能，产生协同效应。将VCR和QU共包封于同一LPNs中具有作为克服化疗耐药性淋巴瘤的新型治疗方法的潜力。
